文献速递心外重症与机械循环支持先天性心脏病外科

儿童限制型心肌病心室辅助装置支持:临床结局与血流动力学

Ventricular assist device support in paediatric patients with restrictive cardiomyopathy-clinical outcomes and haemodynamics.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

基于EUROMACS数据库的回顾性分析纳入44例<19岁限制型心肌病患儿,中位植入年龄5.0岁,中位支持95.5天。59.1%过渡至心脏移植,36.4%死亡;1年和2年移植概率与扩张型心肌病相当(52.3% vs 51.4%和59.5% vs 60.1%,P=0.868),但死亡率更高(35.8% vs 17.0%和35.8% vs 19.0%,P=0.005)。VAD支持后肺动脉压改善,6例因肺动脉高压初始被判定不适合移植的患儿最终成功移植。

要点

  • 儿童限制型心肌病VAD支持后移植率与扩张型心肌病相当,但死亡率更高。
  • 不良事件率高:脑血管意外31.8%、泵血栓29.5%、大出血25.0%、最终双心室支持59.1%。
  • VAD支持后肺动脉压改善,部分因肺动脉高压初始不适合移植的患儿最终可移植。

核心结论

  • 儿童限制型心肌病VAD支持罕见,死亡率和不良事件率高,但移植存活率59.1%且移植后30天全部存活。
  • VAD支持期间肺动脉压改善,可能使先前不适合移植的患儿获得移植机会。

研究设计与样本

  • 回顾性数据库分析,纳入EUROMACS数据库中所有<19岁接受VAD支持的受限型心肌病患者,并与扩张型心肌病患者比较。
  • 联系参与中心回顾性提供额外详细超声和Swan Ganz测量,以分析VAD支持对肺动脉压和右心室功能的影响。

主要发现

  • 受限型心肌病组1年和2年移植概率与扩张型心肌病组相当(52.3% vs 51.4%和59.5% vs 60.1%,P=0.868)。
  • 受限型心肌病组死亡率概率高于扩张型心肌病组(1年35.8% vs 17.0%,2年35.8% vs 19.0%,P=0.005)。
  • 不良事件率高:脑血管意外31.8%、泵血栓29.5%、大出血25.0%、最终双心室支持59.1%。
  • 心房插管组脑血管意外和泵血栓发生患者数分别为非心房插管组的2倍(21.1% vs 40.0%,P=0.595和15.8% vs 40.0%,P=0.464;可能因样本量小无统计学意义)。

关键数值与推荐

  • 移植概率:受限型心肌病组1年52.3% vs 扩张型心肌病组51.4%,2年59.5% vs 60.1%(P=0.868)。
  • 死亡率概率:受限型心肌病组1年35.8% vs 扩张型心肌病组17.0%,2年35.8% vs 19.0%(P=0.005)。
  • 不良事件率:脑血管意外31.8%、泵血栓29.5%、大出血25.0%、最终双心室支持59.1%。
  • 心房插管组脑血管意外21.1% vs 40.0%(P=0.595),泵血栓15.8% vs 40.0%(P=0.464)。

临床怎么用

  • 儿童限制型心肌病可考虑VAD支持作为过渡至移植,但需注意高死亡率和不良事件率。
  • VAD支持可改善肺动脉压,可能使因肺动脉高压初始不适合移植的患儿最终接受移植。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Restrictive cardiomyopathy is rare and is generally associated with worse clinical outcomes compared to other cardiomyopathies. Ventricular assist device (VAD) support for these children is seldom applied and often hampered by the surgical difficulties. METHODS: All paediatric (<19 years) patients with a restricted cardiomyopathy supported by a VAD from the EUROMACS database were included and compared to patients with a dilated cardiomyopathy (retrospective database analyses). Participating centres were retrospectively contacted to provide additional detailed echo and Swan Ganz measurements to analyse the effect of VAD support on pulmonary artery pressure and right ventricular function. RESULTS: Forty-four paediatric VAD-supported patients diagnosed with restricted cardiomyopathy were included, with a median age at implantation of 5.0 years. Twenty-six of the 44 patient with a restricted cardiomyopathy survived to transplantation (59.1%), 16 died (36.4%) and 2 are still on ongoing VAD support (4.5%) after a median duration of support of 95.5 days (interquartile range 33.3-217.8). Transplantation probability after 1 and 2 years of VAD support in patients with a restricted cardiomyopathy were comparable to patients with a dilated cardiomyopathy (52.3% vs 51.4% and 59.5% vs 60.1%, P = 0.868). However, mortality probability was higher in the restricted cardiomyopathy cohort (35.8% vs 17.0% and 35.8% vs 19.0%, P = 0.005). Adverse event rates were high (cerebrovascular accident in 31.8%, pump thrombosis in 29.5%, major bleeding 25.0%, eventual biventricular support in 59.1%). In the atrially cannulated group, cerebrovascular accident and pump thrombosis occurred in twice as much patients (21.1% vs 40.0%, P = 0.595 and 15.8% vs 40.0%, P = 0.464; probably non-significant due to the small numbers). Pulmonary arterial pressures improved after implantation of a VAD, and 6 patients who were initially labelled as ineligible due to pulmonary hypertension could eventually be transplanted. CONCLUSIONS: VAD support in children with a restricted cardiomyopathy is rarely performed. Mortality and adverse event rates are high. On the other hand, survival to cardiac transplantation was 59.1% with all patients surviving the 1st 30 days after cardiac transplantation. Pulmonary arterial pressures improved while on support, potentially making cardiac transplantation a viable option for previously ineligible children.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Rohde S, Miera O, Sandica E, et al. Ventricular assist device support in paediatric patients with restrictive cardiomyopathy-clinical outcomes and haemodynamics. Eur J Cardiothorac Surg. 2024. PMID: 39029920. doi:10.1093/ejcts/ezae277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。